BEZ235, a novel inhibitor of PI3K and mTOR, exerts antitumor effects against gastric carcinoma and enhances the effects of nab-paclitaxel through inhibition of cell proliferation and modulation of the PI3K/mTOR pathway [76]. Here, PIK3CA is linked to gastric carcinoma.